Science

The NIPD Genetics team has a very strong scientific publication track record in the field of in vitro genetic testing. Our scientists have published several original articles in prestigious peer-reviewed journals describing our innovative scientific work and cutting-edge technological advances.

NIPD Genetics has also presented its pioneering work at several international scientific conferences demonstrating its leadership in the field of genetic testing.

NIPD Genetics has obtained several competitive research grants for the development of novel products, showing its international competitiveness in the field of designing and development of genetic testing technologies and solutions.

Kypri E., Ioannides M., Achilleos A., Koumbaris G., Patsalis P., Stumm M. Non-invasive prenatal screening tests - update 2022. Journal of Laboratory Medicine De Gruyter 2022. https://doi.org/10.1515/labmed-2022-0023

Kyrochristos ID, Glantzounis GK., Goussia A., Eliades A., Achilleos A., Tsangaras K., Hadjidemetious I., Elpidorou M., Ioannides M., Koumbaris G., Mitsis M., Patsalis PC., Roukos D. Comprehensive Spatiotemporal Intra-Patient Heterogeneity for Colorectal Cancer With Liver Metastasis. Frontiers in Oncology 2:855463, 2022. Doi: 10.3389/fonc.2022.855463

Chrysostomou AC., Vrancken B., Koumbaris G., Themistokleous G., Aristokleous A., Masia C., Eleftheriou C., Ioannou C., Stylianou DC., Ioannides M., Petrou P., Georgiou V., Hatziyianni A., Lemey P., Vandamme AM., Patsalis PC., Kostrikis LG. A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic. Viruses 2021, 13, 1098. DOI:  10.3390/v13061098.

Elena Fountzilas, Alexia Eliades, Georgia-Angeliki Koliou, Achilleas Achilleos, Charalambos Loizides, Kyriakos Tsangaras, Dimitrios Pectasides, Joseph Sgouros, Pavlos Papakostas, Grigorios Rallis, Amanda Psyrri, Christos Papadimitriou, Georgios Oikonomopoulos, Konstantinos Ferentinos, Anna Koumarianou, George Zarkavelis, Christos Dervenis, Gerasimos Aravantinos, Dimitrios Bafaloukos, Paris Kosmidis, George Papaxoinis, Maria Theochari, Ioannis Varthalitis, Nikolaos Kentepozidis, Georgios Rigakos, Zacharenia Saridaki, Adamantia Nikolaidi, Athina Christopoulou , Florentia Fostira, Epaminontas Samantas, Elena Kypri, Marios Ioannides, George Koumbaris, George Fountzilas , Philippos C Patsalis. Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. Cancers Jan 8;13(2):198. 2021. Doi: 10.3390/cancers13020198 

Marios Ioannides, Achilleas Achilleos, Skevi Kyriakou, Elena Kypri, Charalambos Loizides, Kyriakos Tsangaras, Louiza Constantinou, George Koumbaris, Philippos C Patsalis. Development of a new methylation-based fetal fraction estimation assay using multiplex ddPCR. Molecular genetics & genomic medicine 8:e1094, 2020. Doi: 10.1002/mgg3.1094

George Koumbaris, Achilleas Achilleos, Michalis Nicolaou, Charalambos Loizides, Kyriakos Tsangaras, Elena Kypri, Petros Mina, Carolina Sismani, Voula Velissariou, Georgia Christopoulou, Pantelis Constantoulakis, Emmanouil Manolakos, Ioannis Papoulidis, Danai Stambouli, Marios Ioannides and Philippos Patsalis. Targeted capture enrichment followed by NGS: development and validation of a single comprehensive NIPT for chromosomal aneuploidies, microdeletion syndromes and monogenic diseases. Molecular Cytogenetics 12:48, 2019. doi: 10.1186/s13039-019-0459-8

Elena Kypri, Marios Ioannides, Evi Touvana, Ioanna Neophytou, Petros Mina, Voula Velissariou, Spiros Vittas, Alfredo Santana, Filippos Alexidis, Kyriakos Tsangaras, Achilleas Achilleos, Philippos Patsalis and George Koumbaris. Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test. Molecular Cytogenetics 12:34, 2019. Doi: 10.1186/s13039-019-0446-0

George Koumbaris, Elena Kypri, Kyriakos Tsangaras, Achilleas Achilleos, Petros Mina, Maria Neofytou, et al., and Philippos C Patsalis Cell-free DNA analysis of targeted genomic regions in maternal plasma for non-invasive prenatal testing of trisomy 21, trisomy 18, trisomy 13 and fetal gender. Clinical Chemistry 62:6, 848-855, 2016

Keravnou A, Ioannides M, Loizides C, Tsangaras K, Achilleos A, Mina P, Kypri E, Hadjidaniel MD, Neofytou M, Kyriacou S, Sismani C, Koumbaris G, Patsalis PC. MeDIP combined with in-solution targeted enrichment followed by NGS: Inter-individual methylation variability of fetal-specific biomarkers and their implementation in a proof of concept study for NIPT. PLoS One. 2018 Jun 11;13(6):e0199010. doi: 10.1371/journal.pone.0199010. eCollection 2018

Neofytou MC, Tsangaras K, Kypri E, Loizides C, Ioannides M, Achilleos A, Mina P, Keravnou A, Sismani C, Koumbaris G, Patsalis PC. Targeted capture enrichment assay for non-invasive prenatal testing of large and small size sub-chromosomal deletions and duplications. PLoS One. 2017 Feb 3;12(2):e0171319. doi: 10.1371/journal.pone.0171319. eCollection 2017.

Keravnou A, Ioannides M, Tsangaras K, Loizides C, Hadjidaniel MD, Papageorgiou EA, Kyriakou S, Antoniou P, Mina P, Achilleos A, Neofytou M, Kypri E, Sismani C, Koumbaris G, Patsalis PC. Whole-genome fetal and maternal DNA methylation analysis using MeDIP-NGS for the identification of differentially methylated regions. Genet Res (Camb). 2016 Nov 11;98:e15.

Koumbaris G, Kypri E, Tsangaras K, Achilleos A, Mina P, Neofytou M, Velissariou V, Christopoulou G, Kallikas I, González-Liñán A, Benusiene E, Latos-Bielenska A, Marek P, Santana A, Nagy N, Széll M, Laudanski P, Papageorgiou EA, Ioannides M, Patsalis PC. Cell-Free DNA Analysis of Targeted Genomic Regions in Maternal Plasma for Non-Invasive Prenatal Testing of Trisomy 21, Trisomy 18, Trisomy 13, and Fetal Sex. Clin Chem. 2016 Jun;62(6):848-55. doi: 10.1373/clinchem.2015.252502.

Ioannides M, Papageorgiou EA, Keravnou A, Tsaliki E, Spyrou C, Hadjidaniel M, Sismani C, Koumbaris G, Patsalis PC. Inter-individual methylation variability in differentially methylated regions between maternal whole blood and first trimester CVS. Mol Cytogenet. 2014 Nov 1;7(1):73. doi: 10.1186/s13039-014-0073-8. eCollection 2014.

Papageorgiou EA, Koumbaris G, Kypri E, Hadjidaniel M, Patsalis PC. The Epigenome View: An Effort towards Non-Invasive Prenatal Diagnosis. Genes (Basel). 2014 Apr 9;5(2):310-29. doi: 10.3390/genes5020310.

Antoniou P, Michalokopoulos S, Ioannides M, Papageorgio EA, Patsalis PC. Identifying Differentially Methylated Regions by efficient bit-masking of DNA microarrays to use as markers for Non Invasive Prenatal Diagnosis. Engineering Intelligent Systems. 2014 Mar; 22(1).

Kyriakou S, Kypri E, Spyrou C, Tsaliki E, Velissariou V, Papageorgiou EA, Patsalis PC. Variability of ffDNA in maternal plasma does not prevent correct classification of trisomy 21 using MeDIP qPCR methodology. Prenat Diagn. 2013 Apr 25. doi: 10.1002/pd.4140.

Papageorgiou EA, Tsaliki E, Koumbaris G, Patsalis PC. Author’s response regarding “MeDIP-qPCR approach for non-invasive prenatal diagnosis of Down syndrome: accuracy and reproducibility”. Prenat Diagn. 2013 Apr;33(4):404-5. doi: 10.1002/pd.4048.

Papageorgiou EA, Patsalis PC. Maternal plasma sequencing: a powerful tool towards fetal whole genome recovery. BMC Med. 2013 Feb 27;11(1):56. doi:10.1186/1741-7015-11-56.

Patsalis PC. Technical concerns about immunoprecipitation of methylated fetal DNA for noninvasive trisomy 21 diagnosis. Nat. Med. 2012 Sep 7;18(9):1328-9. doi: 10.1038/nm.2914.

Patsalis PC, Papageorgiou EA. Non-Invasive Prenatal Diagnosis (NIPD) of Down Syndrome using real time qPCR. ECA Newsletter, July 2012.

Velissariou V, Patsalis PC. The Future of Prenatal Diagnosis of Genetic Diseases of the Embryo: Non-Invasive Prenatal Diagnosis in free DNA of the Pregnant Woman. Medical Analects, July-September 15:713-717, 2012.

Patsalis PC. A new method for non-invasive prenatal diagnosis of Down Syndrome using MeDIP real time qPCR. Applied & Translational Genomics 1 (2012) 3-8, 2012.

Tsaliki E, Papageorgiou EA, Spyrou C, Koumbaris G, Kypri E, Kyriakou S, Sotiriou C, Touvana E, Keravnou A, Karagrigoriou A, Lamnissou K, Velissariou V, Patsalis PC. MeDIP real-time qPCR of maternal peripheral blood reliably identifies trisomy 21. Prenat Diagn. 2012 Oct;32(10):996-1001 doi: 10.1002/pd.3947. [Epub 20, 12 Jul 26].

Papageorgiou EA, Patsalis PC. Non Invasive prenatal diagnosis of aneuploidies: new technologies and clinical applications. Genome Medicine. 2012 May 28;4(5):46. (Epub ahead of print).

Patsalis PC, Tsaliki E, Koumbaris G, Karagrigoriou A, Velissariou V, Papageorgiou EA. A new non-invasive prenatal diagnosis of Down syndrome through epigenetic markers and real-time qPCR. Expert Opin Biol Ther. 2012 Jun;12 Suppl 1:S155-61. Epub 2012 Apr 14.

Koumbaris G, Hatzisevastou-Loukidou H, Alexandrou A, Ioannides M, Christodoulou, C, Fitzgerald T, Rajan D, Clayton S, Kitsiou-Tzeli S, Vermeesch JR, Skordis N, Antoniou P, Kurg A, Georgiou I, Carter NP, Patsalis PC. FoSTeS, MMBIR and NAHR at the human proximal Xp region and the mechanisms of human Xq isochromosome formation. Hum Mol Genet. 2011 May 15;20(10):1925-36. Epub 2011 Feb 24.

Papageorgiou EA, Karagrigoriou A, Tsaliki E, Velissariou V, Carter NP, Patsalis PC. Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat Med. 2011 Apr;17(4):510-3. Epub 2011 Mar 6.

  • Title: “A single comprehensive NIPT for aneuploidies, microdeletions and point mutations”, 3rd Symposium on Clinical Genetics & Genomics & 19th Educational Seminar in Genetics, 31 May-1 June 2019, Athens-Greece.
  • Title: “New Advancements in NIPT for prenatal screening of genetic diseases”, The 10th International Symposium on Diabetes, Hypertension, Metabolic Syndrome and Pregnancy, 29 May – 1 June 2019, Florence-Italy.
  • Title: “New Generation Non-Invasive Genetic Testing for the Detection of Chromosomal Syndromes, Microdetion and Single Gene Diseases”, 4th Scientific Conference: "Prenatal Diagnosis and Treatment of Fetus", 18 May 2019, Athens-Greece.
  • Title: “Clinical utility of tissue and plasma DNA profiling of solid tumor cancer patients”, 2nd Conference “Genetic Innovations in 2019”, 7 February 2019, Kaunas, Lithuania.
  • Title: “Liquid Biobsy”, Annual Conference of ISMPO (India Society of Medical & Paediatric Oncology) - ISMPOCON JAIPUR 2018, 16-18 November 2018.
  • Title:’Genomics’, The omics & maternal-fetal - neonatal medicine from top research to the bed side; can we predict pregnancy complications? XXVI European Congress of the European Association of Perinatal Medicine, 5-8 September 2018, St. Petersburg, Russia.
  • Title: “cfDNA: Single gene disorders”, 17th World Congress in Fetal Medicine, 24-28 June 2018, Athens-Greece.
  • Title: “NIPT Beyond Aneuploidies”, Corporate Satellite Session during ESHG 2018 Conference, 17 June 2018, Milan-Italy.
  • “The Genome”. The 9th International Symposium on Diabetes, Hypertention, Metabolic Syndrome and Pregnancy, DIPAP2017, Barchelona, Spain, 8 March 2017, Invited Lecturer.
  • Title: “Genetics, Material Fetal Medicine and the Great Obstretrical Syndromes”. The 9th International Symposium on Diabetes, Hypertention, Metabolic Syndrome and Pregnancy, DIPAP2017, Barchelona, Spain, 8 March 2017.
  • Title: “A New Generation Non-invasive Prenatal Test for Genetics Disorders”. The First International Personalized Medicine Congress. Tehran. Iran. February 24-27, 2017.
  • Title: “Circulating Tumour DNA as a Non-invasive Biomarker in Cancer”. Genetics in Oncology, University of Kaunas, Kaunas, Lithuania. February 1-3, 2017.
  • Title: “Non Invasive Prenatal Testing of Genetic Disorders”. The 1st Asia-Pacific Symposium on Diabetes, Hypertention, Metabolic Syndrome and Pregnancy, DIPAP2016, Colombo, Sri Lanka, 8-10 September 2016.
  • Title: “Genetics Meets Fetal and Perinatal Medicine”. The 1st Asia-Pacific Symposium on Diabetes, Hypertention, Metabolic Syndrome and Pregnancy, DIPAP2016, Colombo, Sri Lanka, 8-10 September 2016.
  • Title: “Non Invasive Prenatal Diagnosis of Chromosomal Disorders”. 2nd International Conference of the Hellenic Society of Human Genetics, Athens, Greece. 4-6 November 2016, Invited Lecturer.
  • Title: “Non Invasive Prenatal Diagnosis of Genomic Disorders”. 5th International Conference of the Cyprus Society of Human Genetics, Nicosia, Cyprus. 14-15 October 2016.
  • Title: “When IVF meets NIPT: Another challenge to look at…”. Annual Meeting of the National Society of Obstetric and Gynegology, Tel Aviv, Israel. 8 March 2016.
  • Title: “Multiplex Parallel Analysis of Targeted Genomic Regions for NIPT”. Molecular Diagnostic Europe, Lisbon, Portugal. 4-7 April 2016.
  • Title: “New Generation Non-Invasive Prenatal Diagnosis with competitive advandages”, Eurogenetics Center, Thessaloniki, Greece, 25 April, 2016.
  • Title: “NIPT: Present and Future”, Two Forum – EXPO Athens, Athens, Greece.
  • Title: “Non-Invasive Prenatal Diagnosis using cffDNA”, Biomedical Center, Thessaloniki, Greece, 26 April, 2016.
  • Title: “Non-Invasive Prenatal Diagnosis using cffDNA”, University of Ioannina, Greece, 29 June, 2016.
  • Title: “Non-Invasive Prenatal Diagnosis of aneuploidies”, Biomedical Center, Athens, Greece,15 June, 2016.
  • Title: “The Veracity Test. Advances in Fetal Medicine Course. London, UK, 5-7 December 2015.
  • Title: “Development and Validation of the Veracity Non Invasive Prenatal Test., Advances in Prenatal Diagnosis. 16-19 November 2015. Boston, USA.
  • Title: “Development and Validation of the Veracity: a non-invasive prenatal test”, Vilnious University, Lithuania, 7 November, 2015.
  • Title: “Barriers and Drivers for the Implementation of Clinical Sequencing: An International Discussion Symposium”, American Society of Human Genetics Meeting, 6-10 October, 2015, Baltimore, USA. Invited Lecturer, Plenary Lecture.
  • Title: “Development and Validation of the Veracity: a newly highly accurate and cost effective non-invasive prenatal test”, Advance course in Ultrasound and Fetal Medicine, 2-4 October 2015, Belfast, UK.
  • Title: “Development and Validation of the Veracity: a non-invasive prenatal test”, Pan-Hellenic Perinatal Conference, 15-18 October 2015, Athens, Greece.
  • Title: “DNA-based Non Invasive Prenatal Diagnosis for Down Syndrome”, World Medical Summit, 7-9 July 2015, Macau, China.
  • Title: “Non Invasive Prenatal Diagnosis”, Lithuenian Academy of Science, Vilnious, Lithuenia, 16 December 2014.
  • Title: “Non Invasive Prenatal Diagnosis of Genetic Diseases”. Femmes d’ Europe, Brussels, Belgium, 16 October 2013.
  • Title: “Non Invasive Prenatal Diagnosis of Genetic Disorders”. BrainTrain EU Conference, Riken Institute, Yokahama, Japan, 19 September 2013.
  • Title: “Development of a New Non-Invasive Prenatal Diagnostic Method using Peripheral Maternal Blood Sample”. 1st Conference of the Society of Medical Geneticists, 30 May to 1 June 2013, Greece, Athens.
  • Title: “Non-Invasive Prenatal Diagnosis: From inception of the idea to the development of the product”. University of Ioannina School of Medicine, Ioannina, Greece.
  • Title: “Non Invasive prenatal diagnosis”. 11th World Congress in Fetal Medicine, 24-28 June 2012, Kos, Greece.
  • Title: “Further development and larger validation of non-invasive prenatal diagnosis for trisomy 21 using MeDIP real time qPCR”. European Society of Human Genetics 2012, 23-26 June 2012, Nurnberg, Germany.
  • Title: “Non-Invasive Prenatal Diagnosis for Trisomy 21 using MeDIP real time qPCR”. 4th Slovene Medical Genetics Symposium – New technologies and approaches in medical genetic diagnostics, 6 April 2012, Ljubljana, Slovenia.
  • Title: “Prenatal Diagnosis of Genetic Disorders: From Invasive to Non Invasive Prenatal Diagnosis”. International Down Syndrome Day, Hadassah Hospital, 22 March 2012, Jerusalem, Israel.
  • Title: “Development and Commercial Exploitation of Non-Invasive Prenatal Diagnosis”. Advanced Technologies in Medicine, Conference in Innovation, University of Crete, 25 – 26 February 2012, Greece, Cyprus.
  • Title: “Non-Invasive Prenatal Diagnosis of Down Syndrome”. 14th Conference of the Italian Society of Human Genetics (XIV SIGU), 13-16 Nov 2011, Milan, Italy.
  • Title: “Non-Invasive Prenatal Diagnosis of Down Syndrome”. 7th International Conference on Circulating Nucleic Acids in Plasma and Serum (CNAPS VII), 24-25 Oct 2011, Madrid, Spain.
  • Title: “Fetal-specific DNA methylation ratio permits non-invasive prenatal diagnosis of trisomy 21”. Cold Spring Harbor Laboratory: Personal Genomes, 30 Sept – 2 Oct 2011, New York, USA.
  • Title: “From invasive to non-invasive prenatal diagnosis”. The 5th International Conference on Birth Defects and Disabilities in the Developing World, 24-27 September 2011, Lodz, Poland.
  • Title: “Non-Invasive Prenatal Diagnosis of Down Syndrome”, Isida Clinic, 16 Sept 2011, Kiev, Ukraine.
  • Title: “Development and Validation of Non-Invasive Prenatal Diagnosis for Trisomy 21”. 8th European Cytogenetics Conference, European Cytogenetic Association, 2-5 July, 2011, Porto, Portugal.
  • Title: “Diagnosis of Aneuploides: Epigenetic Approach – Fetal-Specific DNA Methylation Ration Permits Non-Invasive Prenatal Diagnosis of Trisomy 21”. 10th Fetal Medicine World Congress, 26-30 June 2011, Malta.
  • Title: “Development and Validation of Non-Invasive Prenatal Diagnosis of Trisomy 21”. European Genetics Conference, European Society of Human Genetics, 28-31 May, 2011, Amsterdam, Netherlands.
  • Title: “Non-Invasive Prenatal Diagnosis of Down Syndrome”. University of Ioannina Medical School, 23 May, 2011, Ioannina, Greece.
  • Title: “Non-Invasive Prenatal Diagnosis of Down Syndrome”. Annual Conference of UK Clinical Molecular Genetics Society and UK Association of Clinical Cytogenetics, 4-8 April, 2011, Durham, UK.
  • Title: “Non-Invasive Prenatal Diagnosis of Down Syndrome”. MHTERA Hospital, 2-4 December 2010, Athens, Greece.

  • Title: Development of a novel, Preimplantation Genetic Testing (PGT) Kit. Competitive grant by Research Promotion Foundation, Cyprus.
  • Title: Accelerating the commercialization of non-invasive tests for liquid biopsy of solid tumor cancers (LIQ-BIOPSY). Competitive grant by Research Promotion Foundation, Cyprus.
  • Title: Proof of Concept study for ERC NIPD discovered biomarkers (mR-NIPD). Competitive grant by European Research Council (ERC) Proof of Concept Grant, European Union.
  • Title: A novel non-invasive prenatal diagnosis of genetic disorders (NIPD). Competitive grant by European Research Council (ERC) Advanced Investigator Grant, European Union.
  • Title: A new genetic laboratory for non-invasive prenatal diagnosis (ANGELAB). Competitive grant by 7th Framework Programme (ICT), European Union.
  • Title: Development and validation of a non-invasive prenatal diagnostic (NIPD) kit for aneuploidy detection (NIPD-KIT). Competitive grant by Eurostars Program, European Union and Cyprus Research Promotion Foundation.
  • Title: Development of an innovative non-invasive prenatal diagnostic test (NIPD21). Competitive grant by Ministry of Energy, Commerce, Industry and Tourism, Cyprus.
  • Title: Using fetal specific methylated markers for the development of non-invasive prenatal diagnosis for Down Syndrome. Competitive grant by Research Promotion Foundation (RPF) Young Researcher Award, Cyprus.
  • Title: Methods and compositions for non-invasive prenatal diagnosis
    of fetal aneuploidies. Competitive grant by Research Promotion Foundation Innovation, Cyprus

Latest from our Blog

Neothetis-01.jpg
14 Sep 2022 News

NIPD GENETICS, A MEDICOVER COMPANY ANNOUNCES THE ADDITION OF 6 NEW NEOTHETIS LIQUID BIOPSY TESTS FOR THERAPY SELECTION

September 14th, 2022: NIPD Genetics announces the addition of 6 new NeoThetis liquid biopsy tests for therapy selection, which include Breast & Gynecological, Gastric, Melanoma, …

 Read More
ESMO Website Post 1080x1080.png
22 Aug 2022 News

ESMO 2022: NIPD GENETICS WILL BE ATTENDING THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS IN PARIS

ESMO 2022: NIPD GENETICS WILL BE ATTENDING THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS IN PARIS

We are pleased to announce that we will be …

 Read More
InterGenetics media publication.jpg
02 Aug 2022 News

MEDICOVER EXPANDS INTO GENETIC TESTING IN GREECE BY ACQUIRING INTERGENETICS, CENTER FOR MEDICAL GENETICS AND GENOMICS

Medicover, a leading international healthcare and diagnostic services company, announces the acquisition of InterGenetics Center for Medical Genetics and Genomics in Greece, thus strengthening its …

 Read More
medicover-01.jpg
11 Jul 2022 News

MEDICOVER AWARDED AT THE 10TH INVEST CYPRUS INTERNATIONAL INVESTMENT AWARDS

July 11th, 2022

Medicover was honoured at the prestigious 10th Invest Cyprus International Investment Awards, which recognize foreign companies, individuals, and investors for their contribution …

 Read More
View All Posts

NIPD Genetics - Privacy Policy

General Statement

NIPD Genetics is a leading, innovative biotechnology company that designs, develops, and provides a broad spectrum of healthcare services to its customers through its expansive portfolio of molecular and clinical laboratory tests in all disciplines.

At NIPD Genetics we are committed to protecting and respecting our customer’s privacy and personal information. Personal information or personal data means any information that identifies, relates to, describes, is capable of being associated with, or could be reasonably linked, directly or indirectly, with a particular individual, such as name, identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that individual.

NIPD Genetics collects and processes your personal information according to the General Data Protection Regulation (EU) 2016/679 and the Cypriot law providing for the protection of natural persons with regards to the processing of personal data and for the free movement of such data (L. 125(I)/2018). The following principles lie at the heart of our approach to handling personal data:

NIPD Genetics has appointed a Data Protection Officer (DPO) who is responsible for overseeing and ensuring that personal information is collected and processed in line with these principles. The contact details of the Data Protection Officer (DPO) can be found below:

Email address: dpo@nipd.com

Postal address: 31 Neas Engomis street, 2409 Engomi, Nicosia, Cyprus

Telephone number: + 357 22266888

By accessing or using our products or services, or by transmitting information to us by email or other electronic means, you accept our policies, procedures and practices described in this Privacy Policy. If you do not agree with our policies, procedures and practices as described, you can choose not to access or use our products or services or not to transmit personal information to us.

This Privacy Policy applies to NIPD Genetics facilities, its websites www.nipd.com, www.nipdlabs.com, www.nipdlabs.com.cy and their subdomains, that link to this privacy pol icy.

PERSONAL INFORMATION COLLECTION AND PROCESSING

We collect and process several types of personal information from and about users of our websites and of our products and services, including:

Information about children

If you are under 18 years of age, do not register on our website or provide any information about yourself to us. We do not provide our products or services directly to children or proactively collect their personal information. Despite this prohibition, it is possible that we may sometimes be given information about children while handling samples from our customers in our clinical labs, or through use of our products and services by our customers and partners. If we become aware that we have inadvertently collected personal information from children under the age of 18, without parental consent, we will take the necessary steps to delete it as soon as possible in compliance with applicable laws.

LEGAL BASIS FOR PROCESSING OF YOUR PERSONAL INFORMATION

Your personal information is collected by NIPD Genetics for the following purposes:

  1. To provide you with our products and services, respond to your inquiries or fulfill your requests and otherwise manage your relationship with us. The legal basis for processing is to meet the requirements of a contract, to comply with our legal obligations and/or because we have a legitimate interest in responding to requests for information about our products and services.
  2. To communicate with you about content and product offerings, newsletters and event invitations which are relevant to your interests and in line with your preferences. The legal basis for processing is the individual’s explicit consent prior to sending the information and managing individuals preferences.
  3. To process and respond to complaints. The legal basis for processing is to meet a legal obligation.
  4. To monitor and record information relating to the use of our products and services, including our website. The legal basis for processing is our legitimate interest in order to improve our products and services and our website for individuals.

To provide our products and services, NIPD Genetics may collect, receive and process biological samples to isolate and sequence DNA. NIPD Genetics may then store resulting genetic information and use genetic information to provide our products and services. In some cases, NIPD Genetics may provide interpretations of genetic information on behalf of its customers, including healthcare providers. This is only done pursuant to a written contract or a Sample Information Form with a patient’s informed consent and is subject to applicable legal and ethical safeguards.

This sensitive information described above is collected by NIPD Genetics for the following purposes:

  1. To provide support and maintenance services to customers who use our products and services – The legal basis for processing is to meet the requirements of a contract.
  2. To provide genotyping and sequencing services and analysis for our customers, including healthcare providers. The legal basis of this processing is to meet the requirements of a contract or as allowed in the Sample Information Form with a patient’s informed consent.
  3. To conduct genotyping and sequencing services and analysis for quality control, process and product development and improvements, and optimization in our labs to reflect quality improvements and advances in our technology. The legal basis for processing is the patient’s informed consent given through the Sample Information Form.

Transfer of Data

Your information, including personal data, may be transferred to - and maintained on - computers located outside your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

NIPD Genetics will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal information will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the General Data Protection Regulation and will not sell or trade your personal information.

NIPD Genetics may disclose your personal information in the good faith that such action is necessary:

COOKIES AND OTHER TRACKING TECHNOLOGIES

Cookies are files with small amount of data which may include an anonymous unique identifiers. Cookies are sent to your browser when you visit a website and stored on your device. Tracking technologies used on the website are beacons, tags and scripts, to collect and track information and to improve and analyze our websites.

We use cookies and similar tracking technologies to track the activity on our websites and collect certain information. This includes information about the computer or device you are using, such as Internet protocol (IP) address, information about the browser type or version, the pages of our website that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our websites.

Examples of Cookies we may use:

Session Cookies. We use Session Cookies to operate our websites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the websites

Keyword cookies. To understand how visitors discover the websites.

ANALYTICS

We may use third-party Service Providers to monitor and analyze the use of our websites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

SECURITY OF DATA

We are committed to protecting the security of the information we collect, and we take reasonable physical, technical, and administrative safeguards such as data anonymization and encryption to help protect personal information from unauthorized or inappropriate access or use. It is your responsibility to protect the confidentiality of your passwords, and any other access features associated with your access or use of the website or our products and services, as well as to adhere to any applicable Terms of Use or other contract between us and you or your organization.

PERSONAL DATA RETENTION

We may retain collected information even after you remove it from the website, our Services, or our Products, to comply with applicable law, to resolve disputes, to enforce any rights in connection with the website, our Services, or our Products, and to use as provided in this Privacy Policy, the Terms of Use, or an applicable contract between us and you or your organization. How long we retain specific personal information varies depending on the purpose for its use and we may delete or retain your personal information in accordance with applicable law.

SERVICE PROVIDERS

We may employ third party companies and individuals to facilitate, maintain or operate our websites (“Service Providers”), to provide the websites on our behalf, to perform service-related services or to assist us in analyzing how our websites are used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

LINKS TO OTHER SITES

Our websites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

CHANGES TO THIS PRIVACY POLICY

This Privacy Policy may be updated from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our website, prior to the change becoming effective and update the “effective date” at the bottom of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

YOUR LEGAL RIGHTS

NIPD Genetics ensures that it can respond immediately to requests that you make for the exercise of your legal rights in accordance with data protection laws. These rights are as follows:

You also have the right to lodge a complaint at any time to the Office of the Commissioner for Personal Data Protection.

We encourage you to contact us, should you wish to practice any of your legal rights or you have any questions about this Privacy Policy, by sending an email to NIPD Genetics’ Data Protection Officer at dpo@nipd.com.

Effective date: 18/06/2021

Ok got it!